Organovo Announces Appointment of Gregory T. Lucier as Corporate Advisor

   Organovo Announces Appointment of Gregory T. Lucier as Corporate Advisor

PR Newswire

SAN DIEGO, Aug. 6, 2014

SAN DIEGO, Aug. 6, 2014 /PRNewswire/ --Organovo Holdings, Inc. (NYSE MKT:
ONVO) ("Organovo"), a three-dimensional biology company focused on delivering
breakthrough 3D bioprinting technology, announced today that Gregory T. Lucier
has been appointed as a corporate advisor. In the role, Mr. Lucier will
advise Chief Executive Officer Keith Murphy and the executive management team
on various corporate issues.

"As Organovo moves towards launch of a major new offering, our 3D Human Liver
Tissue, we have been putting the pieces in place to execute on our opportunity
and deliver results to shareholders," stated Organovo Chief Executive Officer
Keith Murphy. "We have been hiring for key roles, building the necessary
internal processes, and driving our scientists to finalize the tissue
production and testing protocols. Bringing on someone who can assist the
company in our launch stage and during our commercial growth is critical.
Given his tremendous track record of success at Life Technologies, no one is
better for this role than Greg Lucier."

"I'm pleased to be asked to help the executive management of Organovo deliver
on the promise of three dimensional bioprinting," said Greg Lucier. "As I
have learned more about Organovo's team and technology, it's clear there is a
compelling opportunity to advance their early scientific performance into
strong commercial wins. I look forward to using my leadership experience,
strategic thinking in the life sciences industry, and track record bringing
biomedical commercial solutions to market, to help guide the company in its
next phase."

Mr. Lucier was formerly Chairman and CEO of Life Technologies, a global life
sciences company acquired by Thermo Fisher Scientific for $15.6.billion in
2014. During Mr. Lucier's 11-year tenure at Life Technologies, he led the
company from a small start-up known as Invitrogen in 2003, directed the
acquisition and merger of Invitrogen with Applied Biosystems in 2008 into the
renamed Life Technologies, and then transformed the organization by 2013 into
a global, world-leading biotechnology firm with 50,000 products, 12,000
employees and nearly $4 billion in sales in more than 180 countries. Serving
in his leadership role, Mr. Lucier was responsible for fostering a culture of
excellence at Life Technologies, and applied his more than 25 years of
strategic management experience to help champion an era of personalized

Prior to his tenure at Life Technologies, Mr. Lucier was a corporate officer
of General Electric Company where he served in a variety of leadership roles.
Mr. Lucier received a bachelor's degree in engineering with honors from
Pennsylvania State University, and an MBA from Harvard Business School. He
serves on the boards of NuVasive Corporation, RainTree Oncology Services,
CareFusion, and is board chairman for Sanford Burnham Medical Research

AboutOrganovo Holdings, Inc.
Organovodesigns and creates functional, three-dimensional human tissues for
medical research and therapeutic applications. The Company is collaborating
with pharmaceutical and academic partners to develop human biological disease
models in three dimensions. These 3D human tissues have the potential to
accelerate the drug discovery process, enabling treatments to be developed
faster and at lower cost. The company plans to market the first product of a
planned portfolio offering, a 3D Human Liver Tissue for use in Toxicology and
other preclinical drug testing prior to the end of 2014, and remains on track
to bring this breakthrough technology to customers. In addition to numerous
scientific publications, the Company's technology has been featured inThe
Wall Street Journal,Time Magazine, The Economist, and numerous
others.Organovois changing the shape of medical research and practice. Learn
more at

Safe Harbor Statement

Any statements contained in this press release that do not describe historical
facts may constitute forward-looking statements as that term is defined in the
Private Securities Litigation Reform Act of 1995. Any forward-looking
statements contained herein are based on current expectations, but are subject
to a number of risks and uncertainties. The factors that could cause actual
future results to differ materially from current expectations include, but are
not limited to, risks and uncertainties relating to the Company's ability to
develop, market and sell products based on its technology; the expected
benefits and efficacy of the Company's products and technology; the market
acceptance of the Company's products; and the Company's business, research,
product development, regulatory approval, marketing and distribution plans and
strategies. These and other factors are identified and described in more
detail in our filings with the SEC, including our annual report on Form 10-K
filed with theSEConJune 10, 2014as well as our other filings with
theSecurities and Exchange Commission. You should not place undue reliance on
these forward-looking statements, which speak only as of the date that they
were made. These cautionary statements should be considered with any written
or oral forward-looking statements that we may issue in the future. Except as
required by applicable law, including the securities laws ofthe United
States, we do not intend to update any of the forward-looking statements to
conform these statements to reflect actual results, later events or
circumstances or to reflect the occurrence of unanticipated events.

SOURCE Organovo Holdings, Inc.

Contact: Investor Contact, Barry Michaels, Chief Financial Officer,
858-224-1000, ext. 3,; or Gerry Amato, Booke & Company
Investor Relations,; or Media Contact, Mike Renard, EVP,
Commercial Operations, 858-224-1006,
Press spacebar to pause and continue. Press esc to stop.